32 Investor presentation Full year 2023 Pipeline supports significant grow strategic focus areas PHASE 1 NN1845 – GSI NN1471 – Pumpinsulin NN9041 – DNA Immunotherapy PHASE 2 NN9506 – GELA NN9440 – INV-202 NN9505 – GELA PHASE 3 NN1535 – I NN9924 – O NN9388 – C NN9542 – OW GLP-1/GIP co-agonist NN7533 – Ndec in SCD NN9904 – OW oral sema NN9650 – OM GLP-1 /GIP NN9487 – Oral Amycretin NN9490 – Sc Amycretin NN6582 – LXR(a) in MASH NN6561 – VAP-1i in MASH NN6581 – MARC1 in MASH NN9003 – Stem Cells in HF NN9001 – Stem Cells in PD NN6491 – Anti-ANGPTL3 in CVD NN7536 – Etavopivat in Thalassemia NN7537 – Evavopivat MDS NN9931 – Gilead in MASH NN9500 – FGF-21 in MASH NN6019 – Coarmitug in ATTR Cardiomyopathy NN9440 - INV-202 in CKD NN9536 – S NN9838 – C NN9932 – O NN9931 – S NN6535 – O NN6018 – Z NN6018 – Z NN6023 – O NN7769 – M NN7535 – E Other PH SOUL – Ora FOCUS – Se FLOW – Sem STRIDE – Se STEP – Sem Diabetes care Obesity care Rare blood disorders Rar 1 Submitted to EMA; 2 Submitted to EU for HwI, to Japan for HA/HB; 3 H igher doses of injectable semaglutide (8 mg and 16 mg) tested Approved for PH1 by FDA. AATLD: Alpha-1 Antitrypsin Deficiency-associated Liver Disease; AD: Alzheimer’s Disease; ANGPTL3: Angio disease; CVOT: Cardiovascular outcome trial; FGF-21: Fibroblast growth factor 21; GHD: Growth hormone disorder; GSI: Glucose Sen inhibitors; JP: Japan; LXR(a): Liver X receptor alpha; MARC1: Mitochondrial amidoxime reducing component 1; MASH: Metabolic dysf arterial disease; PD: Parkinson’s Disease; PH: Primary hyperoxaluria; SCD: Sickle cell disease; Sema: Semaglutide; US: United States;
Download PDF file